Abstract:Abstract Introduction Acute panmyelosis with myelofibrosis (APMF) is classified under acute myeloid leukemia not otherwise specified by World Health organization (WHO). The clinical course of this entity is rapidly progressive and fatal, therefore, it is essential to make the accurate diagnosis and distinguish it from its mimickers, particularly acute megakaryoblastic leukemia; AML-M7 (AMKL). The main objective of this study is to identify clinical and pathologic features which could help distinguish APMF from AMKL. Methods We evaluated all patients treated at our institution between 1994 and 2013, with APMF and AMKL. We retrospectively reviewed their clinical data, laboratory results, and initial bone marrow morphologic evaluation. The lineage of blasts was evaluated using immunohistochemical staining with antibodies to CD34, anti-megakaryocyte antibodies CD41, CD61, and polyclonal factor VIII. Flow cytometry and cytogenetic studies were reviewed. Results i) Clinical characteristics 28 patients were studied which included 8 with APMF (median age 63 years) and 20 with AMKL (median age 65 years). Splenomegaly was commonly seen in AMKL (40%) as opposed to APMF (12.5%) (P=0.21). None of the APMF patients had an antecedent hematologic malignancy, compared to 50% of AMKL patients (p=0.02). Accordingly, APMF patients had a lower incidence of the JAK2V617F mutation compared to AMKL (14% vs. 78%, p=0.04). ii) Pathological features Patients with APMF had a hypercellular marrow with increased erythropoiesis (87% vs. 10%, p<0.01) and granulopoiesis (100% vs. 25%, p<0.01), with lower bone marrow blast percentage (14% vs. 33%, p<0.01), with all blasts staining positive for CD34 (p=0.23) compared with AMKL. In AMKL, the majority of blasts stain positive for anti-megakaryocytic antibodies CD61 (100% vs. 30%, p=0.02), CD41 (75% vs. 20%, p=0.10), and factor VIII (50% vs. 20%, p=0.02). On flow cytometry, all cases of APMF demonstrated multilineage proliferation with subsets of blasts positive for CD61, CD117, and MPO. In comparison, all cases of AMKL expressed megakaryocytic marker CD61. iii) Treatment Half of our patients received intensive induction chemotherapy in each group. Median survival was similar in APMF and AMKL of 8.6 and 7.6 months respectively (P=0.82). Of the 8 APMF patients, two are alive, with follow-up duration of 14 and 20 months, respectively. In the AMKL group, only one patient is alive, with follow-up duration of 55 months. All three patients have undergone allogeneic bone marrow transplant. Conclusion In summary, our study illustrated important clinical and pathologic differences between APMF and AMKL, two similar but distinct conditions. Allogenic stem cell transplant has shown promise in limited number of cases. Future trials evaluating the efficacy of novel therapies are warranted.Table 1Clinical and Laboratory features including treatment details of patients with APMF and AMKLAPMFN=8AMKLN=20P-valueAge in years (median)63650.11Gender, M:F5:310:100.69Splenomegaly at diagnosis, n (%)1 (12.5)8 (40)0.21Antecedent hematological malignancy08- myeloproliferative neoplasm 2- myelodysplastic syndromes0.02Hgb [median] g/dl9.68.70.73WBC [median] x 109/L1.14.40.15Platelets [median ] X 109/L28360.29Blast % [median]2130.47LDH [median]4227090.12JAK2V617F mutation, n (%)1/7 (14)7/9 (78)0.04Bone marrow Cellularity, n (%): - Hypercellular - Normocellular - Hypocellular8 (100) 13 (65) 4 (20) 3 (15)0.07 0.29 0.54↑erythropoiesis, n (%)7 (87)2 (10)<0.01Left shift, n (%)5 (62)6 (30)0.20↑granulopoiesis, n (%)8 (100)5 (25)<0.01Left shift, n (%)8 (100)9 (55)0.01↑megakaryopoiesis, n (%)7 (87)16 (80)1.00Micromegakaryocytes, n (%)7 (87)18 (90)1.00↓megakaryocyte nuclear lobulation, n(%)7 (87)12 (60)0.21Clustering of megakaryocytes, n (%)5 (62)13 (65)1.00BM blast % [median]3314<0.01% of blasts CD34 + [median]100300.23% of blasts + for megakaryocyte markers [median] - CD61+ - CD41+ - Factor VIII+30 20 20100 75 500.020.10 0.01Reticulin fibrosis ≥ 3+, n (%)5 (62)9 (45)0.67Complex karyotype, n (%)4(50)10(50)1.00Treatment, n (%) - Induction chemotherapy - Hypomethylating agent - Clinical trial - Supportive care4 (50) 0 0 4(50)10(50) 2(10) 2 (10) 6(30)Allogeneic bone marrow transplant, n (%)3 (38)3 (15)Overall survival in months (median)8.677.610.82 Disclosures No relevant conflicts of interest to declare.

A Rare Pediatric Case Report With Review of Literature for the Diagnosis of Acute Megakaryoblastic Leukemia (FAB M7)

FEATURES OF A DIFFERENTIAL DIAGNOSIS OF PEDIATRIC ACUTE MONOCYTIC LEUKEMIA (AML-M5a) ON THE EXAMPLE OF A CLINICAL CASE

Acute Megakaryoblastic Leukemia in Children and Adolescents: A Retrospective Analysis of 24 Cases

Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia With Unusual Immunophenotype

Acute Megakaryocytic Leukemia (M7) in Children

ACUTE MEGAKARYOBLASTIC LEUKEMIA (AML-M7) IN 10-MONTH-OLD BABY BOY WITH DOWN SYNDROME

Mixed Phenotype Acute Leukemia With Pml-Rar Alpha Positive: A Case Report And Literature Review

New treatment regimen for acute megakaryoblastic leukemia with BCR-ABL positive: case report and literature review

Clinical Diagnosis of Adult Patients with Acute Megakaryocytic Leukemia

Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children

Mixed Phenotype Acute Leukemia with PML-RARα Positive: a Case Report and Literature Review

Pediatric Acute Megakaryoblastic Leukemia Without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-Bfmsg)

A Case of Acute Megakaryocytic Leukemia Presenting As Peripheral Acute Leukemia with Complex Karyotypic Abnormalities

Humeral Diaphyseal Osteolytic Lesion as the Initial Presentation of Acute Myeloid Leukemia in a Child: A Case Report and Review of the Literature

Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia

Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene

Heterogeneous Cytogenetic Subgroups And Outcomes In Childhood Acute Megakaryoblastic Leukemia: A Retrospective International Study

Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype

Liver fibrosis among infants with t(1;22)(p13;q13) acute megakaryoblastic leukemia: a case report and literature review

Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic Leukemia Without Down Syndrome

Comparison of Acute Panmyelosis with Myelofibrosis and Acute Megakaryoblastic Leukemia: A Mayo Clinic Study